20 completed, 7 recruiting, 6 terminated, 4 withdrawn. 26 Phase 2, 15 Phase 1, 4 Phase 3, 3 Early Phase 1.
Follow siltuximab: new trials by email Literature Review of siltuximab trials Research Report on siltuximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001) MK-6255, CD8 PET Tracer, Acetaminophen - Ovarian Neoplasms, Endometrial Neoplasms | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 80 | 2026-11-13 | 2026-10-13 |
| A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) MK-1045, Acetaminophen (or similar antipyretic), Diphenhydramine (or similar antihistamine) - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 60 | 2026-10-09 | 2026-10-08 |
| A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 340 | 2026-05-18 | 2026-10-19 |
| A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation Siltuximab, Placebo - Antibody Mediated Rejection of Lung Transplant | Phase 1 | Recruiting | Washington University School of Medicine | 30 | 2025-11-06 | 2026-08-27 |
| A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma Siltuximab - CRS - Cytokine Release Syndrome, Myeloma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-08-10 | 2025-08-06 |
| Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab Siltuximab, Epcoritamab, Gemcitabine and oxaliplatin - Non-Hodgkin Lymphoma, Cytokine Release Syndrome | Phase 1 | Recruiting | Taylor Brooks | 20 | 2025-01-14 | 2026-06-25 |
| Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM Siltuximab, Teclistamab(FDA-approved) - Multiple Myeloma, Cytokine Release Syndrome | Phase 2 | Withdrawn | Jack Khouri, MD | 2025-01-01 | 2025-03-03 | |
| A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant Siltuximab, Melphalan - Multiple Myeloma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 215 | 2024-11-06 | 2026-10-01 |
| Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Biopsy - Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Recruiting | Yuanquan Yang | 40 | 2024-07-09 | 2026-09-28 |
| Screening Trial for Pain Relief in Schwannomatosis (STARFISH) Siltuximab, Erenumab-Aooe, Siltuximab Matching Placebo - Schwannomatosis, Schwannomas | Phase 2 | Recruiting | Massachusetts General Hospital | 40 | 2023-08-31 | 2026-07-24 |
| Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM Siltuximab - Acute Myeloid Leukemia (AML) | Phase 1 | Unknown | Nantes University Hospital | 12 | 2023-03-16 | 2023-04-06 |
| Siltuximab in Large Granular Lymphocytic Leukemia (LGLL) Siltuximab - Large Granular Lymphocyte Leukemia | Early Phase 1 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 6 | 2023-02-15 | 2026-02-05 |
| Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma Biospecimen Collection, Computed Tomography, Positron Emission Tomography - Non-Hodgkin Lymphoma | Phase 1 | Completed | Timothy Voorhees | 11 | 2023-01-31 | 2025-01-31 |
| Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Siltuximab - Cytokine Release Syndrome, ICANS | Phase 2 | Completed | University of Alabama at Birmingham | 20 | 2021-11-15 | 2026-07-27 |
| Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease Siltuximab - Idiopathic Multicentric Castleman's Disease | Phase 2 | Terminated | RECORDATI GROUP | 22 | 2021-03-31 | 2021-04-19 |
| SILtuximab in Viral ARds (SILVAR) Study Siltuximab, Normal Saline - Acute Respiratory Distress Syndrome, Lung Diseases | Phase 3 | Terminated | RECORDATI GROUP | 555 | 2020-11-13 | 2021-04-19 |
| Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19 Interleukin 6 (IL6) Antagonist, Interleukin 6 (IL6) Antagonist and corticosteroids, corticosteroid alone - Critical Illness, Corona Virus Infection | Unknown | King Faisal Specialist Hospital & Research Center | 860 | 2020-07-22 | 2021-03-08 | |
| Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia Siltuximab, Dexamethasone - COVID-19 | Phase 2 | Completed | Judit Pich MartÃnez | 163 | 2020-04-15 | 2023-09-21 |
| Treatment of COVID-19 Patients With Anti-interleukin Drugs Usual Care, Anakinra, Siltuximab - COVID-19 | Phase 3 | Completed | University Hospital, Ghent | 342 | 2020-04-03 | 2023-03-14 |
| Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer Siltuximab, Spartalizumab - Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 1 / Phase 2 | Completed | Emory University | 35 | 2020-01-17 | 2025-08-22 |
Showing 20 of 43. Sign in to see all of them.
Multiple Myeloma (13) · Cytokine Release Syndrome (5) · Lymphoma, Non-Hodgkin (4) · Neoplasms, Plasma Cell (4) · Multi-centric Castleman's Disease (3) · Prostatic Neoplasms (3) · COVID-19 (2) · Carcinoma, Renal Cell (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Recurrence (2) · Respiratory Distress Syndrome (2) · Acute Lung Injury (1) · Anemia (1)
Centocor, Inc. (8) · Janssen Research & Development, LLC (7) · Merck Sharp & Dohme LLC (3) · Memorial Sloan Kettering Cancer Center (2) · RECORDATI GROUP (2) · SWOG Cancer Research Network (2) · Brian Miller (1) · Carla Greenbaum, MD (1) · Emory University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Jack Khouri, MD (1) · Janssen Pharmaceutical K.K. (1) · Judit Pich MartÃnez (1) · King Faisal Specialist Hospital & Research Center (1)
United States (31) · Belgium (10) · France (10) · Spain (10) · United Kingdom (8) · Netherlands (7) · Israel (6) · Australia (5) · Canada (5) · Germany (5) · Russia (5) · South Korea (5) · Brazil (3) · China (3) · Czechia (3)
Amitkumar Mehta, MD (1) · Bart Lambrecht, MD, PhD (1) · Brady Stein, MD (1) · Carla Greenbaum, MD (1) · Chris Keuker, MD (1) · Derek Byers, MD, PhD (1) · Gunjan Shah (1) · Gunjan Shah, MD, MS (1) · Jacek K. Pinski, MD (1) · Jacek Pinski, MD (1)
PMID 20484019, PMID 24833354, PMID 25042199, PMID 25294016, PMID 25655379, PMID 28087540, PMID 30890552, PMID 32493441, PMID 33935163, PMID 34600589, PMID 34756178, PMID 35080773, PMID 35793409, PMID 36798353
2008 (2), 2025 (2), U10CA032102 (2), 2009 (1), P30CA060553 (1), P30CA138292 (1), R61HL169189 (1)